Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del

New England Journal of Medicine

Volumn 377, Issue 21, 2017, Pages 2013-2023

  Taylor Cousar, Jennifer L ^a   Munck, Anne ^b   McKone, Edward F ^c   Van Der Ent, Cornelis K ^d   Moeller, Alexander ^e   Simard, Christopher ^f   Wang, Linda T ^f   Ingenito, Edward P ^f   McKee, Charlotte ^f   Lu, Yimeng ^f   Lekstrom Himes, Julie ^f   Elborn, J Stuart ^g,h  

^a DEPARTMENT OF MEDICINE   (United States)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f VERTEX PHARMACEUTICALS   (United States)

^g ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IVACAFTOR; PLACEBO; TEZACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; INDOLE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CFTR GENE; CHILD; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GENE; GENE MUTATION; HEADACHE; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; ADOLESCENT; BODY MASS; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HOMOZYGOTE; MUTATION; PATHOPHYSIOLOGY; QUALITY OF LIFE; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPHENOLS; BENZODIOXOLES; BODY MASS INDEX; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HOMOZYGOTE; HUMANS; INDOLES; MALE; MUTATION; QUALITY OF LIFE; QUINOLONES; YOUNG ADULT;

EID: 85034765653     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1709846     Document Type: Article

References (39)

1. Elborn JS. Cystic fibrosis. Lancet 2016; 388:2519-31.
2. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891-904.
3. Cystic Fibrosis Foundation. Clinical and Functional TRanslation of CFTR (CFTR2). Baltimore: Johns Hopkins University (http://cftr2.org/index.php).
4. ECFS Patient Registry: annual data report: 2014 data. Karup, Denmark: European Cystic Fibrosis Society, 2016 (https:// www.ecfs.eu/projects/ecfs-patient-registry/ annual-reports).
5. Cystic Fibrosis Foundation Patient Registry: 2015 annual data report. Bethesda, MD: Cystic Fibrosis Foundation, 2016 (https://www.cff.org/Our-Research/CF-Patient-Registry/2015-Patient -Registry-Annual-Data-Report.pdf).
6. The Canadian Cystic Fibrosis Registry: 2015 annual report. Cystic Fibrosis Canada, 2017. (http://www.cysticfibrosis.ca/uploads/ Registry%20Report%202015/2015%20 Registry%20Annual%20Report%20EN .pdf).
7. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991;354:526-8.
8. Lukacs GL, Chang XB, Bear C, et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane: determination of functional half-lives on transfected cells. J Biol Chem 1993;268:21592-8.
9. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290:L1117-L1130.
10. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009;106:18825-30.
11. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187:1219-25.
12. De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551Dgating mutation. J Cyst Fibros 2014;13:674-80.
13. McKone EF, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014;2:902-10.
14. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72.
15. Kalydeco (ivacaftor). Boston: Vertex Pharmaceuticals, 2017 (package insert) (http://pi.vrtx.com/files/uspi_ivacaftor.pdf).
16. Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014;13:29-36.
17. Bessonova L, Higgins M, Volkova N, et al. Analysis of real-world outcomes in patients with CF treated with ivacaftor from the 2014 US and UK CF registries. Pediatr Pulmonol 2016;51:Suppl 45:S381. abstract.
18. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011;108:18843-8.
19. Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med 2017;5:107-18.
20. Milla CE, Ratjen F, Marigowda G, et al. Lumacaftor/ivacaftor in patients aged 6-11 years with cystic fibrosis and homozygous for F508del-CFTR. Am J Respir Crit Care Med 2017;195:912-20.
21. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373: 220-31.
22. Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2017;5:557-67.
23. Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and Cystic Fibrosis Patient Registry data. Am J Respir Crit Care Med 2015;192:836-42.
24. Hubert D, Chiron R, Camara B, et al. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros 2017;16:388-91.
25. Jennings MT, Dezube R, Paranjape S, et al. An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on lumacaftor/ivacaftor. Ann Am Thorac Soc 2017 April 13 (Epub ahead of print).
26. Labaste A, Ohlmann C, Mainguy C, et al. Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis. J Cyst Fibros 2017 May 18 (Epub ahead of print).
27. Orkambi (lumacaftor/ivacaftor). Boston: Vertex Pharmaceuticals, 2016 (package insert) (http://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf).
28. Van Goor F, Grootenhuis PD, Hadida S, et al. Nonclinical profile of the CFTR corrector VX-661. Pediatr Pulmonol 2016; 51:Suppl 45:S274. abstract.
29. Donaldson SH, Pilewski JM, Griese M, et al. Tezacaftor/ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med 2017 September 20 (Epub ahead of print).
30. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88.
31. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
32. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-8.
33. Liou TG, Elkin EP, Pasta DJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010;9:250-6.
34. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med 2014;161:233-41.
35. Bradley JM, Blume SW, Balp MM, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J 2013; 41:571-7.
36. de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680-5.
37. 1 in adults with cystic fibrosis. J Cyst Fibros 2012;11:405-11.
38. Stephenson AL, Tom M, Berthiaume Y, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J 2015;45:670-9.
39. Centers for Disease Control and Prevention. About adult BMI. 2017 (https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html).